NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
NATCO Pharma Dividend Announcement
• NATCO Pharma announced a quarterly dividend of ₹3.00 per ordinary share which will be made payable on 2024-09-11. Ex dividend date: 2024-08-23
• NATCO Pharma annual dividend for 2024 was ₹4.25
• NATCO Pharma annual dividend for 2023 was ₹9.50
• NATCO Pharma's trailing twelve-month (TTM) dividend yield is 0.4%
• NATCO Pharma's dividend growth over the last five years (2018-2023) was 2.25% year
• NATCO Pharma's dividend growth over the last ten years (2013-2023) was 9.04% year
NATCO Pharma Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-08-23 | ₹3.00 | quarterly | 2024-09-11 |
2024-02-26 | ₹1.25 | quarterly | |
2023-11-24 | ₹1.25 | quarterly | 2023-12-14 |
2023-08-22 | ₹7.00 | quarterly | 2023-09-08 |
2023-02-21 | ₹1.25 | quarterly | 2023-03-01 |
2022-11-21 | ₹0.75 | quarterly | 2022-12-10 |
2022-08-19 | ₹3.50 | quarterly | 2022-08-30 |
2022-02-24 | ₹2.00 | quarterly | 2022-03-16 |
2021-11-23 | ₹0.50 | quarterly | 2021-12-11 |
2021-08-24 | ₹2.00 | quarterly | 2021-08-31 |
2021-02-22 | ₹1.00 | quarterly | 2021-03-13 |
2020-11-24 | ₹3.00 | quarterly | 2020-12-12 |
2020-08-21 | ₹1.25 | quarterly | 2020-08-31 |
2020-06-26 | ₹1.00 | quarterly | 2020-07-05 |
2020-02-24 | ₹3.50 | quarterly | 2020-03-13 |
2019-11-21 | ₹1.00 | quarterly | 2019-11-29 |
2019-08-22 | ₹1.25 | quarterly | 2019-08-29 |
2019-06-06 | ₹1.25 | quarterly | 2019-06-14 |
2019-02-21 | ₹3.50 | quarterly | 2019-03-14 |
2018-08-20 | ₹1.50 | quarterly | 2018-08-27 |
2018-02-15 | ₹7.00 | quarterly | 2018-03-08 |
2017-08-16 | ₹1.25 | quarterly | 2017-08-23 |
2017-02-23 | ₹6.00 | quarterly | 2017-03-16 |
2016-08-19 | ₹0.75 | quarterly | 2016-08-31 |
2016-02-22 | ₹1.25 | quarterly | |
2015-02-24 | ₹5.00 | quarterly | 2015-03-06 |
2014-02-24 | ₹5.00 | quarterly | 2014-03-06 |
2013-02-22 | ₹4.00 | quarterly | 2013-03-06 |
NATCO Pharma Dividend per year
NATCO Pharma Dividend growth
NATCO Pharma Dividend Yield
NATCO Pharma current trailing twelve-month (TTM) dividend yield is 0.4%. Interested in purchasing NATCO Pharma stock? Use our calculator to estimate your expected dividend yield:
NATCO Pharma Financial Ratios
NATCO Pharma Dividend FAQ
Other factors to consider when evaluating NATCO Pharma as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy NATCO Pharma stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: NATCO Pharma's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, NATCO Pharma publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, NATCO Pharma distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from NATCO Pharma are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: NATCO Pharma sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, NATCO Pharma distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: NATCO Pharma declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of NATCO Pharma's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review NATCO Pharma's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.